How do I treat diabetic ketoacidosis? by Reusch, C E
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
How do I treat diabetic ketoacidosis?
Reusch, C E
Abstract: Unspecified
DOI: 10.1080/00325481.1985.11698880
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-68279
Accepted Version
Originally published at:
Reusch, C E (2012). How do I treat diabetic ketoacidosis? In: Southern European Veterinary Confer-
ence (International Society of Feline Medicine), Barcelona, 18 October 2012 - 20 October 2012. DOI:
10.1080/00325481.1985.11698880
How do I treat diabetic ketoacidosis? 
Claudia E. Reusch 
Prof. Dr., Dipl ECVIM-CA 
Clinic for Small Animal Internal Medicine 
Vetsuisse Faculty, University of Zurich 
Winterthurerstrasse 260 
CH-8057 Zurich 
 
Diabetic ketoacidosis (DKA) may be the cause for first presentation of a patient or may occur at any 
time during the treatment of diabetes mellitus. In some dogs and cats DKA may be a recurrent 
disorder, either because of repetitive management faults or due to the presence of a chronic 
concurrent disease. Clinical signs of DKA include anorexia, lethargy, weakness, vomiting, abdominal 
pain, dehydration and possibly stupor or coma. The typical signs of diabetes (pu/pd, polyphagia) are 
often no longer present at the time of presentation. Diagnosis of DKA requires a high index of 
suspicion, in particular in patients in which diabetes has not been noticed previously. The diagnosis is 
established in the presence of hyperglycemia, moderate to severe concentrations of ketones in urine 
or blood and anion-gap acidosis. β-hydroxybutyrate is the most abundant ketone body in patients with 
DKA. However, it is not detected by the commonly used urine test strips, and therefore ketonuria may 
be underestimated and the diagnosis of DKA may even be missed. Recently, a hand-held meter 
(Precision Xceed, Abbott Laboratories) has been validated for use in dogs and cats which is easy to 
use and allows detection of β-hydroxybutyrate in serum.
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Many animals have concurrent disease such as pancreatitis, hepatic lipidosis syndrome (cats), urinary 
tract infection, hypercortisolism, neoplasia or renal failure, and therefore a variety of additional 
laboratory abnormalities may be found.    
DKA is one of the most complex metabolic emergencies and its treatment is highly demanding. It 
usually requires  hospitalisation of the patient in a 24-hour facility in which frequent reevaluations of 
physical and laboratory variables and adjustment of therapy is feasible.
3
 The major life-threatening 
abnormalities are dehydration (due to osmotic diureses, anorexia, vomiting), hyperosmolarity (due to 
hyperglycemia and water loss) and metabolic acidosis (due to increased ketogenesis). The 
fundamental principles of treatment are: fluid therapy, electrolyte supplementation, insulin 
administration and treatment of concurrent diseases. 
Fluid therapy  
IV fluid therapy should be initiated immediately. 0.9% NaCl is considered the initial fluid of choice 
because most patients are hyponatremic on presentation. The amount of fluid is calculated based on 
the degree of dehydration + maintenance + ongoing losses:  
Dehydration deficit (ml) = % dehydration x body weight in kg x 10;   
Maintenance =  60 ml/kg/24 h (for cats and for dogs between 10 – 20 kg, the volume is higher in 
smaller, less in bigger dogs); 
Ongoing losses = estimated loss due to vomiting, diarrhoe, osmotic diureses (at least  2.5 – 5% of kg 
body weight).  
The total amount is given over 12 – 24 hours. Reassessment should be done often, in particular 
during the early phases of therapy. It is important to remember, that the calculation of fluid deficits are 
estimates and that requirements may be higher, in particular in cases with severe osmotic diuresis.  
0.9% saline is a non-buffered solution which may contribute to metabolic acidosis. We therefore 
consider to switch to a buffered crystalloid solution (such as Plasma- Lyte) as soon as serum 
phosphorus level is constant and phosphate supplemenation no longer needed (see later).  
 
 
 
 
Potassium supplementation 
The potassium deficit can be severe, although serum potassium concentration may be normal or even 
elevated. The initial dose depends on the pretreatment potassium concentration. Intravenous 
potassium administration should not exceed 0.5 mmol/kg/h to avoid cardiac arrhythmias.  
 
serum potassium 
mmol/l 
mmol/l KCl added per liter 
of 0.9% NaCl 
maximum rate 
ml/kg/h 
3.6 – 5.0 20 24 
3.1 – 3.5 30 16 
2.6 – 3.0 40 11 
2.1 – 2.5 60 8 
< 2.0 80 6 
 
The serum potassium concentration should be reevaluated 2 hours after initiating therapy and then 
every 4 – 6 hours thereafter.  
 
Phosphate supplementation 
Similar to potassium, the organism is phosphate deficient, regardless of the serum phophorus 
concentration. We usually supplement phosphate by adding half of the calculated dose of potassium 
supplementation as potassium phosphate and the other half as potassium chloride. We do not mix 
potassium phosphate with calcium containing fluids, such as Ringers solution and Plasma-Lyte. 
 
Bicarbonate supplementation 
The metabolic acidosis typically resolves with fluid therapy and insulin administration. The use of 
sodium bicarbonate is controversial in human and veterinary medicine. Sodium bicarbonate therapy in 
DKA may have detrimental effects: e.g. worsening of hypokalemia, decrease of oxygen release at the 
tissue level, paradoxic central nervous system acidosis.
4
 We do not recommend to use sodium 
bicarbonate in patients with DKA. 
    
Insulin therapy 
Insulin therapy is essential in the treatment of DKA, because without insulin ketonemia does not 
resolve and ketogenesis continues. However, an additional effect of insulin is a shift of potassium into 
cells, which may lead to life-threatening hypokalemia in potassium depleted individuals. Therefore, 
insulin therapy should be postponed until potassium (and phophorus) have been supplemented and 
serum levels are stable. We routinely wait for 4 – 6 hours until insulin therapy is started. Short-acting 
insulins (regular insulins or insulin analogues) are the insulins of choice for DKA. In our hospital we 
use NovoRapid (insulin aspartat), a human insulin analog.  Two protocols are known: intermittent, 
intramuscular technique and continuous rate infusion.  
Intermittent, intramuscular technique 
Short acting insulin is given i.m. at a dose of 0.05 – 0.1 U/kg every hour and blood glucose 
concentration is measured prior to each application. The desired decrease of blood glucose 
concentration is 3 – 4 mmol/l per hour until a blood glucose concentration between 12 and 15 mmol/l 
is reached. If the blood glucose concentration decreases to less than 12 mmol/l, glucose is added to 
the intravenous fluid solution to make a 5% glucose solution (e.g. 100 ml 50% glucose to 1000 ml 
0.9% NaCl). Short acting insulin is then given every 4 – 6 hours at a dose of 0.1 – 0.3 U/kg s.c.  
Continuous rate infusion  
This protocol involves administration of short-acting insulin diluted in 0.9% NaCl using an intravenous 
infusion pump in a separate line. An insulin solution is made by adding a dose of 2.2 U/kg short-acting 
insulin for dogs and 1.1 U/kg for cats to 250 ml 0.9% NaCl. Glucose is added to the insulin solution as 
soon as blood glucose falls below 15 mmol/l.
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blood glucose concentration 
mmol/l 
i.v. fluid solution infusion rate  
ml/h 
> 15 0.9% NaCl 10 
 12 - 15 0.9% NaCl + glucose 
5% final glucose concentration  
7 
8 - 12 0.9% NaCl + glucose 
5% final glucose concentration 
5 
5 - 8 0.9% NaCl + glucose 
5% final glucose concentration 
5 
< 5 stop insulin infusion  
 
 
Independent of the protocol, treatment with longer acting insulin is initiated when the patient has been 
stabilized and has begun to eat.  
In Zurich duration of hospitalisation is between 2 days and 2 weeks (mean 7 days).  
Prognosis is largely dependent on the intensity of treatment and monitoring and on  concurrent 
diseases. Mortality ranges between 20 – 30%.  
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